Aptean Expands Text Analytics Capabilities With TheySay Acquisition
ALPHARETTA, Ga., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Aptean, a leading global provider of mission-critical enterprise software solutions, has acquired TheySay, a best-in-market text analytics platform that uses advanced computational linguistics and deep learning to help customers effectively monitor, manage and optimize their reputations and business.
Aptean had already partnered with TheySay to provide sentiment analysis on social media and email channels for Aptean's Respond product, an enterprise complaint management solution companies use to provide timely responses to customer feedback.
"TheySay offers some really exciting technology that help customers understand and respond faster to feedback, predict trends and monitor their reputations, which given the power of social media is more important than ever," said Aptean CEO Kim Eaton. "We're looking forward to continuing to add TheySay's capabilities to Respond and exploring additional uses across our portfolio."
TheySay provides advanced text analytics and emotional intelligence solutions to analyze data from multiple sources and rapidly interpret them for various signals, such as sentiment and other emotions. This helps businesses form a consolidated view of opinions, moods and intent expressed by their customers and other key audiences. That capability allows them to more effectively handle complaints, predict trends and identify underlying risks and opportunities impacting their organizations.
TheySay offers three products:
- PreCeive REST API, TheySay's plug-and-play SaaS product for advanced text analytics, which enriches raw text data with best-in-breed sentiment, emotion, topic and other rich signals.
- MoodRaker, which offers fine-grained, high-coverage opinion streams across social media and news sources in real time to analyze key performance indicators and predict trends and behaviors around unlimited topics.
- Evamind, the company's search and data exploration platform for large-scale knowledge discovery and opinion mining.
"Our relationship with Aptean and integration of our capabilities into Respond has opened the door to an exciting new chapter for TheySay," said Dr. Karo Moilanen, founder and chief technology officer of TheySay. "We're excited about joining Aptean and becoming part of such a respected company that can offer additional support and scale for our technology. We see a very bright future for TheySay's emotion AI technology across Aptean's extensive, multi-industry product suite."
The purchase of TheySay is Aptean's 16th acquisition since 2015. Financial terms of the sale will not be disclosed.
A spin-off from the Department of Computer Science, University of Oxford, TheySay was established in 2011 and co-founded by Professor Stephen Pulman and Dr. Karo Moilanen. London-based TheySay develops leading-edge text analytics and emotion AI (artificial intelligence) software and solutions based on advanced natural language processing (NLP) and deep learning technology. Global customers encompass a wide array of vertical markets, some of which include financial services, healthcare and media. The company also works with leading systems integrators.
Aptean is a leading global provider of mission-critical enterprise software solutions. We build, acquire and integrate industry-focused solutions to support the evolving operational needs of our customers, enabling them to increase operational efficiencies and improve customer satisfaction and loyalty. To learn how Aptean can help your organization stay at the forefront of your industry, visit www.aptean.com.
Aptean is a trademark of Aptean, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
FOR MORE INFORMATION
Stephanie Zercher, Aptean
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aptean via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
VITEC's EZ TV Video Wall Solution Wins Best of Show Award at the 2018 NAB Show26.4.2018 19:00 | Pressemelding
VITEC's EZ TV Video Wall Solution Wins Best of Show Award at the 2018 NAB Show SUNNYVALE, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced that the new EZ TV video wall processor, available within the award-winning EZ TV IPTV and Digital Signage Platform, was recognized with a Best of Show Award at the 2018 NAB Show from Sound & Video Contractor (SVC) magazine. Evaluated by a panel of industry experts, the Best of Show Award winners were selected based on innovation, feature set, cost efficiency, and performance in serving the industry. VITEC's video wall solution is designed to simplify deployment and management of projects involving IPTV, digital signage, and video wall content, while delivering a breathtaking visual experience. The new EZ TV video wall processors are 100 percent hardware-based, feature low-latency native playback of IPTV streams up to 4K, and support interactive content, video, a
Inspiration in Receipt of Crypto Currency Proposal26.4.2018 16:54 | Pressemelding
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) is pleased to announce that it is contemplating upon the request of Compassion Cannabis that it is allowed to accept crypto currency for settlement for any transactions that occur. The logic is that it would make for easy settlement in any jurisdiction. The Company is not adverse to this proposal, but must perform its due diligence and will table the matter at the AGM. Compassion Cannabis is an Ontario Corp., which has expertise to forward various facets of the explosive new market of the marijuana industry, including but not limited to the "Vape" market and dispensary centers for the industry. We believe this will be an extremely lucrative space with tremendous demand in the medical cannabis industry. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not revi
SNOMED International Announces Brazil as its 33rd Member26.4.2018 15:12 | Pressemelding
London, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- Brazil's Ministry of Health and SNOMED International announce that as of April 1, 2018, Brazil has joined the organization as SNOMED International's thirty-third Member. With SNOMED CT already used in various parts of the country, Brazil joined SNOMED International to support nationwide health system transformation as a foundational element of its ehealth Strategy, digiSUS. As outlined in this national strategy, the SUS Monitoring and Evaluation Department of Brazil's Ministry of Health is responsible overall for governance of the National Electronic Health Strategy and its related evaluation and development. Demonstrated through its membership in SNOMED International, Brazil has defined SNOMED CT as the chosen international reference terminology for use in its clinical systems supporting the national ehealth strategy. SNOMED CT is the world's most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOME
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 201826.4.2018 14:30 | Pressemelding
Management to host conference call WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days. About Minerva Neurosciences Mine
Talend Data Fabric Now Certified on MapR Converged Data Platform Version 6.026.4.2018 14:11 | Pressemelding
Latest Release of Talend's Data Integration Platform Enables Powerful New Use Cases in Data Privacy, Compliance Monitoring, Claims Processing, Retail Optimization, and More REDWOOD CITY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, announced that the latest version of Talend Data Fabric is now certified for version 6.0 of the MapR Converged Data Platform, including MapR-DB and MapR-FS. The MapR Converged Data Platform is the industry's only enterprise-grade software solution that unifies big data and open source technologies with fast, native access to global event streaming, real-time database capabilities, and web-scale storage. Together, Talend and MapR provide a unified, open source-based data storage and management platform for an array of different applications, enabling organizations to harness big data in valuable ways to drive innovation and further their digital transformations. "Talend's powerf
CrownBio Launches New Humanized Target Model for Immunotherapy26.4.2018 14:00 | Pressemelding
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs. Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University. The CD3E model expresses the human form of CD3E and is phenotypically normal with levels
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom